Edition:
United Kingdom

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.37USD
22 Feb 2018
Change (% chg)

$0.01 (+0.74%)
Prev Close
$1.36
Open
$1.35
Day's High
$1.38
Day's Low
$1.35
Volume
13,100
Avg. Vol
85,752
52-wk High
$2.12
52-wk Low
$1.06

Select another date:

Tue, Jan 9 2018

BRIEF-Pluristem Therapeutics Says Co Sold Its Entire Holdings In CHA Biotech Co For About $10.5 Mln

* PLURISTEM THERAPEUTICS - ON JAN 8, CO SOLD ITS ENTIRE HOLDINGS IN CHA BIOTECH CO LTD, CONSISTING OF 400,368 SHARES OF CHA, FOR ABOUT $10.5 MILLION

BRIEF-FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia

* PLURISTEM THERAPEUTICS - U.S. ‍FDA CLEARED CO'S EXPANDED ACCESS PROGRAM FOR USE OF PLX-PAD CELL TREATMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA​

BRIEF-Pluristem enters agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD

* Pluristem enters into agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD Source text for Eikon: Further company coverage:

BRIEF-PLURISTEM PRICES PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE

* PLURISTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE

BRIEF-Pluristem extends trial for treatment of insufficient hematopoietic recovery

* Following approval of israel’s ministry of health, Pluristem extends its trial of plx-r18 to treat insufficient Hematopoietic recovery after bone marrow transplant and opens clinical centers in Israel

BRIEF-Pluristem expands its reach in the treatment of impaired hematopoietic systems

* Pluristem expands its reach in the treatment of impaired hematopoietic systems with a European patent covering PLX-R18 in chemotherapy, ARS, genetic disorders and autoimmune diseases Source text for Eikon: Further company coverage:

BRIEF-FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy

* FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy as treatment for acute radiation syndrome Source text for Eikon: Further company coverage:

BRIEF-Pluristem receives positive feedback from FDA and EMA as co prepares for Phase III trial of PLX-PAD

* Pluristem receives positive feedback from FDA and EMA as company prepares for Phase III trial of PLX-PAD to support recovery from hip fracture

BRIEF-U.S. FDA grants fast track designation to Pluristem's PLX-PAD for treating Critical Limb Ischemia

* U.S. FDA grants fast track designation to Pluristem's PLX-PAD for the treatment of Critical Limb Ischemia (cli)

BRIEF-Pluristem Therapeutics awarded two new patents in Hong Kong

* Awarded two new patents in Hong Kong for critical limb ischemia and muscle regeneration

Select another date: